Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis
Background and Objective: Myasthenia gravis (MG) is an autoimmune neuromuscular disease. Nearly 10–30% of patients with MG are refractory to conventional therapy. Rituximab (RTX), a monoclonal antibody targeting CD20, is increasingly used in autoimmune disorders. We performed a systematic review and...
Na minha lista:
| Principais autores: | , , , , , , |
|---|---|
| 格式: | Artigo |
| 语言: | Inglês |
| 出版: |
Frontiers Media S.A.
2021-10-01
|
| 丛编: | Frontiers in Neurology |
| 主题: | |
| 在线阅读: | https://www.frontiersin.org/articles/10.3389/fneur.2021.736190/full |
| 标签: |
没有标签, 成为第一个标记此记录!
|